Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 
• By Francesca Bruce
  
Reimbursement of PARP inhibitors is restricted in indications where they do not offer value for money, says the Dutch HTA. (Shutterstock)

More from Health Technology Assessment

More from Europe